Improving the accuracy of Alzheimer's disease diagnosis
Reimagining Precision Medicine Approaches to AD Diagnosis
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11077745
This study is looking to improve how we diagnose Alzheimer's and related dementias by testing easy-to-use and affordable tests in people from different backgrounds, especially in Latino/Hispanic and Black/African American communities, to help doctors make better decisions in everyday care.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11077745 on ClinicalTrials.gov |
What this research studies
This research aims to enhance the diagnosis of Alzheimer's disease and related dementias (ADRD) by validating accessible and cost-effective biomarkers in diverse populations. The project will involve recruiting participants from various backgrounds, including significant representation from Latino/Hispanic and Black/African American communities. By utilizing innovative cognitive assessments and brain imaging techniques, the research seeks to create scalable precision medicine tools that can be applied in everyday clinical settings. The study will focus on both clinical and plasma-based biomarkers to improve diagnostic accuracy.
Who could benefit from this research
Good fit: Ideal candidates for participation include individuals from diverse backgrounds, particularly those who are Latino/Hispanic or Black/African American, and who may be experiencing cognitive impairment or dementia.
Not a fit: Patients who do not have cognitive impairment or are not part of the targeted demographic groups may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and equitable diagnoses of Alzheimer's disease, particularly for underrepresented populations.
How similar studies have performed: Previous research has shown promise in using biomarkers for Alzheimer's diagnosis, but this approach aims to address specific health disparities, making it a novel and necessary endeavor.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RABINOVICI, GIL DAN — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: RABINOVICI, GIL DAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome